Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1002) 1002
Publication (114) 114
Dissertation (8) 8
Book Chapter (7) 7
Book Review (5) 5
Magazine Article (5) 5
Conference Proceeding (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (718) 718
fenretinide (533) 533
oncology (467) 467
fenretinide - pharmacology (435) 435
female (365) 365
animals (334) 334
apoptosis (314) 314
index medicus (268) 268
antineoplastic agents - pharmacology (256) 256
apoptosis - drug effects (239) 239
fenretinide - therapeutic use (205) 205
male (172) 172
mice (172) 172
cancer (169) 169
cell line, tumor (167) 167
tumor cells, cultured (158) 158
biochemistry & molecular biology (154) 154
n-retinamide (154) 154
retinoids (143) 143
breast-cancer (137) 137
rats (130) 130
neuroblastoma (129) 129
tretinoin - pharmacology (125) 125
chemoprevention (121) 121
tretinoin - analogs & derivatives (118) 118
retinoic acid (117) 117
expression (115) 115
middle aged (115) 115
fenretinide - administration & dosage (108) 108
induction (108) 108
antineoplastic agents - therapeutic use (102) 102
4-hpr (98) 98
dose-response relationship, drug (98) 98
cell division - drug effects (97) 97
cell biology (95) 95
adult (94) 94
prevention (89) 89
pharmacology & pharmacy (88) 88
differentiation (84) 84
aged (81) 81
anticarcinogenic agents - therapeutic use (79) 79
reactive oxygen species - metabolism (79) 79
acid (74) 74
anticarcinogenic agents - pharmacology (73) 73
breast cancer (69) 69
breast neoplasms - prevention & control (68) 68
inhibition (68) 68
article (67) 67
neuroblastoma - drug therapy (65) 65
research (65) 65
cell survival - drug effects (63) 63
flow cytometry (63) 63
time factors (63) 63
lines (62) 62
death (61) 61
growth (61) 61
n- retinamide (61) 61
synthetic retinoid fenretinide (61) 61
vitamin-a (61) 61
cell line (59) 59
breast neoplasms - drug therapy (56) 56
breast neoplasms - pathology (56) 56
drug synergism (55) 55
metabolism (55) 55
vitamin a - blood (55) 55
blotting, western (54) 54
carcinoma-cells (54) 54
gene-expression (53) 53
trans-retinoic acid (53) 53
induced apoptosis (52) 52
cells (50) 50
fenretinide - adverse effects (50) 50
analysis (49) 49
cancer-cells (49) 49
ceramide (49) 49
fenretinide-induced apoptosis (49) 49
tumors (49) 49
in-vitro (48) 48
proteins (48) 48
phase-i trial (47) 47
retinoids - pharmacology (47) 47
tamoxifen (46) 46
reactive oxygen species (45) 45
antineoplastic agents - administration & dosage (44) 44
fenretinide - pharmacokinetics (44) 44
growth-inhibition (44) 44
neuroblastoma - pathology (44) 44
retinoid (44) 44
signal transduction (44) 44
cell death (43) 43
cell proliferation - drug effects (43) 43
therapy (43) 43
activation (42) 42
fenretinide - chemistry (42) 42
health aspects (42) 42
oxidative stress (42) 42
treatment outcome (42) 42
13-cis-retinoic acid (40) 40
caspases - metabolism (40) 40
carcinoma (39) 39
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1000) 1000
Chinese (5) 5
Japanese (5) 5
German (2) 2
Italian (2) 2
Czech (1) 1
French (1) 1
Hungarian (1) 1
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives
by Cooper, Jason P and Reynolds, C Patrick and Cho, Hwangeui and Kang, Min H
Experimental Biology and Medicine, ISSN 1535-3702, 6/2017, Volume 242, Issue 11, pp. 1178 - 1184
Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells. Despite substantial in vitro cytotoxicity, response rates in... 
MEDICINE, RESEARCH & EXPERIMENTAL | Fenretinide | drug formulation development | RANDOMIZED-TRIAL | CELL-LINES | ORGANIZED LIPID COMPLEX | CHILDRENS ONCOLOGY GROUP | THERAPY NANT CONSORTIUM | BREAST-CANCER | PHASE-I TRIAL | LYM-X-SORB (R) | pharmacokinetics | ORAL LEUKOPLAKIA | RESISTANT NEUROBLASTOMA | SYNTHETIC RETINOID FENRETINIDE | fenretinide-LYM-X-SORB (R) | Administration, Oral | Humans | Fenretinide - pharmacology | Treatment Outcome | Antineoplastic Agents - administration & dosage | Lymphoma, T-Cell - drug therapy | Antineoplastic Agents - adverse effects | Fenretinide - pharmacokinetics | Neuroblastoma - drug therapy | Fenretinide - administration & dosage | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Infusions, Intravenous | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Fenretinide - adverse effects | LYM-X-SORB | Pharmacology and Toxicology | fenretinide–LYM-X-SORB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide
by Rahmaniyan, Mehrdad and Curley Jr, Robert W and Obeid, Lina M and Hannun, Yusuf A and Kraveka, Jacqueline M
Journal of Biological Chemistry, ISSN 0021-9258, 07/2011, Volume 286, Issue 28, pp. 24754 - 24764
The dihydroceramide desaturase (DES) enzyme is responsible for inserting the 4,5-trans-double bond to the sphingolipid backbone of dihydroceramide. We... 
METABOLITE 4-OXO-FENRETINIDE | BREAST-CANCER | APOPTOSIS | ORAL FENRETINIDE | BIOSYNTHESIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | IRREVERSIBLE INHIBITION | CHEMOPREVENTION | SPHINGOLIPIDS | CERAMIDE | CELL-DEATH | Oxidoreductases - antagonists & inhibitors | Animals | Oxidoreductases - metabolism | Time Factors | Fenretinide - pharmacokinetics | Cell Line, Tumor | Fenretinide - pharmacology | Rats | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Microsomes, Liver - enzymology | Rats, Sprague-Dawley | Fenretinide | Enzyme Inhibitors | Dihydroceramide Desaturase | Retinoid | Sphingolipid | Lipids | Neuroblastoma | Lipid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Water‐soluble derivatives of 4‐oxo‐N‐(4‐hydroxyphenyl) retinamide: synthesis and biological activity
by Musso, Loana and Tiberio, Paola and Appierto, Valentina and Cincinelli, Raffaella and Cavadini, Elena and Cleris, Loredana and Daidone, Maria Grazia and Dallavalle, Sabrina
Chemical Biology & Drug Design, ISSN 1747-0277, 10/2016, Volume 88, Issue 4, pp. 608 - 614
A novel series of 4‐oxo‐N‐(4‐hydroxyphenyl) retinamide (4‐oxo‐4‐HPR) derivatives were synthesized with the aim of increasing the poor solubility of the parent... 
fenretinide | water‐soluble drugs | 4‐oxo‐4‐HPR | antimitotic activity | antiproliferative activity | Antimitotic activity | Fenretinide | Antiproliferative activity | 4-oxo-4-HPR | Water-soluble drugs | water-soluble drugs | OVARIAN-CANCER CELLS | CHEMISTRY, MEDICINAL | ACID | 4-HPR | BIOCHEMISTRY & MOLECULAR BIOLOGY | RANDOMIZED-TRIAL | INDUCTION | 4-OXO-FENRETINIDE | BREAST-CANCER | PLASMA | FENRETINIDE-INDUCED APOPTOSIS | METABOLITE | Dose-Response Relationship, Drug | Fenretinide - chemistry | Apoptosis - drug effects | Cell Cycle Checkpoints - drug effects | Fenretinide - chemical synthesis | Humans | Solubility | Water - chemistry | Cell Line, Tumor | Fenretinide - pharmacology | Cell Proliferation - drug effects | Fenretinide - analogs & derivatives
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium
by Maurer, Barry J and Kang, Min H and Villablanca, Judith G and Janeba, Jitka and Groshen, Susan and Matthay, Katherine K and Sondel, Paul M and Maris, John M and Jackson, Hollie A and Goodarzian, Fariba and Shimada, Hiroyuki and Czarnecki, Scarlett and Hasenauer, Beth and Reynolds, C. Patrick and Marachelian, Araz
Pediatric Blood & Cancer, ISSN 1545-5009, 11/2013, Volume 60, Issue 11, pp. 1801 - 1808
Background A phase I study was conducted to determine the maximum‐tolerated dose, dose‐limiting toxicities (DLTs), and pharmacokinetics of fenretinide (4‐HPR)... 
neuroblastoma | fenretinide | powder | LYM‐X‐SORB | pediatric | LYM-X-SORB | Fenretinide | Neuroblastoma | Pediatric | Powder | TUMOR-CELL LINES | DIHYDROCERAMIDE DESATURASE | APOPTOSIS | SOLID TUMORS | CHILDRENS ONCOLOGY GROUP | VITAMIN-A | BREAST-CANCER | ONCOLOGY | PEDIATRICS | STAGE-IV | HEMATOLOGY | SYNTHETIC RETINOID FENRETINIDE | N-(4-HYDROXYPHENYL)RETINAMIDE | Humans | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Male | Antineoplastic Agents - administration & dosage | Young Adult | Maximum Tolerated Dose | Antineoplastic Agents - adverse effects | Fenretinide - pharmacokinetics | Neuroblastoma - drug therapy | Adolescent | Fenretinide - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacokinetics | Child | Fenretinide - adverse effects | Consortia | Clinical trials | Reports | Index Medicus | Lym-X-Sorb
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709)
by Judith G. Villablanca and Mark D. Krailo and Matthew M. Ames and Joel M. Reid and Gregory H. Reaman and C. Patrick Reynolds and Children's Oncology Group (CCG 09709)
Journal of Clinical Oncology, ISSN 0732-183X, 07/2006, Volume 24, Issue 21, pp. 3423 - 3430
Purpose To determine the maximal tolerated dosage (MTD) of oral fenretinide given as intact capsules for 7 days, repeated every 21 days, in children with... 
APOPTOSIS | N-(4-HYDROXYPHENYL) RETINAMIDE | CARCINOMA CELLS | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | 13-CIS-RETINOIC ACID | HUMAN BREAST-CANCER | CERAMIDE | NEUROBLASTOMA-CELLS | SYNTHETIC RETINOID FENRETINIDE | CANCER CELL-LINES | Drug Administration Schedule | Administration, Oral | Humans | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Neoplasms - drug therapy | Fenretinide - blood | Antineoplastic Agents - adverse effects | Fenretinide - pharmacokinetics | Neuroblastoma - drug therapy | Adolescent | Antineoplastic Agents - blood | Fenretinide - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacokinetics | Child | Vitamin A - blood | Fenretinide - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Randomized double-blind 2 X 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women
by Decensi, Andrea and Robertson, Chris and Guerrieri-Gonzaga, Aliana and Serrano, Davide and Cazzaniga, Massimiliano and Mora, Serena and Gulisano, Marcella and Johansson, Harriet and Galimberti, Viviana and Cassano, Enrico and Moroni, Simona M and Formelli, Franca and Lien, Ernst A and Pelosi, Giuseppe and Johnson, Karen A and Bonanni, Bernardo
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3749 - 3756
Purpose Tamoxifen and fenretinide are active in reducing premenopausal breast cancer risk and work synergistically in preclinical models. The authors assessed... 
THERAPY | INHIBITION | N-(4-HYDROXYPHENYL) RETINAMIDE | CLINICAL-TRIAL | ONCOLOGY | BINDING PROTEIN-3 | AROMATASE | PHASE-I | EXPRESSION | SYNTHETIC RETINOID FENRETINIDE | GROWTH-FACTOR-I | Multivariate Analysis | Receptors, Estrogen - metabolism | Humans | Middle Aged | Insulin-Like Growth Factor Binding Protein 3 - blood | Receptor, ErbB-2 - metabolism | Premenopause - blood | Tamoxifen - administration & dosage | Incidence | Receptors, Progesterone - metabolism | Antineoplastic Agents, Hormonal - adverse effects | Selective Estrogen Receptor Modulators - therapeutic use | Anticarcinogenic Agents - administration & dosage | Antineoplastic Agents, Hormonal - therapeutic use | Carcinoma, Lobular - prevention & control | Fenretinide - administration & dosage | Adult | Female | Anticarcinogenic Agents - adverse effects | Breast Neoplasms - diagnostic imaging | Odds Ratio | Anticarcinogenic Agents - therapeutic use | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Proportional Hazards Models | Tamoxifen - blood | Treatment Outcome | Mammography | Anticarcinogenic Agents - blood | Antineoplastic Agents, Hormonal - blood | Breast Neoplasms - prevention & control | Biomarkers, Tumor - blood | Drug Synergism | Fenretinide - blood | Fenretinide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Tamoxifen - therapeutic use | Breast Neoplasms - blood | Tamoxifen - analogs & derivatives | Tamoxifen - adverse effects | Insulin-Like Growth Factor I - metabolism | Vitamin A - blood | Carcinoma, Intraductal, Noninfiltrating - prevention & control | Fenretinide - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the children's oncology group
by Villablanca, Judith G and London, Wendy B and Naranjo, Arlene and McGrady, Patrick and Ames, Matthew M and Reid, Joel M and McGovern, Renee M and Buhrow, Sarah A and Jackson, Hollie and Stranzinger, Enno and Kitchen, Brenda J and Sondel, Paul M and Parisi, Marguerite T and Shulkin, Barry and Yanik, Gregory A and Cohn, Susan L and Patrick Reynolds, C
Clinical Cancer Research, ISSN 1078-0432, 11/2011, Volume 17, Issue 21, pp. 6858 - 6866
Purpose: To determine the response rate to oral capsular fenretinide in children with recurrent or biopsy proven refractory high-risk neuroblastoma.... 
BREAST-CANCER | APOPTOSIS | GROWTH-INHIBITION | ONCOLOGY | RETINOIC-ACID | BONE-MARROW | GENE-EXPRESSION | HIGH-RISK NEUROBLASTOMA | STAGE-IV | CANCER CELL-LINES | N-(4-HYDROXYPHENYL)RETINAMIDE | Iodine Radioisotopes | 3-Iodobenzylguanidine - pharmacokinetics | Humans | Neuroblastoma - blood | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Tomography, X-Ray Computed | Antineoplastic Agents - administration & dosage | Young Adult | Capsules | Antineoplastic Agents - adverse effects | Fenretinide - administration & dosage | Female | Antineoplastic Agents - pharmacokinetics | Child | Neoplasm Recurrence, Local - blood | Neuroblastoma - pathology | Radiopharmaceuticals - pharmacokinetics | Administration, Oral | Survival Rate | Disease-Free Survival | Magnetic Resonance Imaging | Fenretinide - blood | Fenretinide - pharmacokinetics | Neuroblastoma - drug therapy | Adolescent | Antineoplastic Agents - blood | Fenretinide - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids
by Valsecchi, Manuela and Aureli, Massimo and Mauri, Laura and Illuzzi, Giuditta and Chigorno, Vanna and Prinetti, Alessandro and Sonnino, Sandro
Journal of Lipid Research, ISSN 0022-2275, 07/2010, Volume 51, Issue 7, pp. 1832 - 1840
The dihydroceramide, ceramide, sphingomyelin, lactosylceramide, and ganglioside species of A2780 human ovarian carcinoma cells treated with the synthetic... 
Fenretinide | 4-HPR | 4-oxo-4-HPR | DIHYDROCERAMIDE DESATURASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | NEUROBLASTOMA | TANDEM MASS-SPECTROMETRY | 4-OXO-FENRETINIDE | CERAMIDE SYNTHASES | METABOLISM | FENRETINIDE-INDUCED APOPTOSIS | SERINE PALMITOYLTRANSFERASE | SPHINGOSINE | fenretinide | GANGLIOSIDE | Fenretinide - therapeutic use | Ovarian Neoplasms - chemistry | Fenretinide - chemistry | Humans | Cell Line, Tumor | Sphingolipids - analysis | Female | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - chemistry | Ovarian Neoplasms - drug therapy | Fenretinide - analogs & derivatives
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure
by Cooper, Jason P and Hwang, Kyunghwa and Singh, Hardeep and Wang, Dong and Reynolds, C Patrick and Curley Jr, Robert W and Williams, Simon C and Maurer, Barry J and Kang, Min H
British Journal of Pharmacology, ISSN 0007-1188, 07/2011, Volume 163, Issue 6, pp. 1263 - 1275
BACKGROUND AND PURPOSE High plasma levels of fenretinide [N‐(4‐hydroxyphenyl)retinamide (4‐HPR)] were associated with improved outcome in a phase II clinical... 
ketoconazole | fenretinide | metabolism | paediatric cancers | GROWTH-INHIBITION | HUMAN BREAST | N-(4-HYDROXYPHENYL) RETINAMIDE | RANDOMIZED-TRIAL | TRANS-RETINOIC ACID | LEUKEMIA CELL-LINES | LUNG-CANCER | ORAL FENRETINIDE | PHASE-I TRIAL | 4-HYDROXYLASE CYP26 | PHARMACOLOGY & PHARMACY | Cell Line | Humans | Microsomes, Liver - metabolism | Fenretinide - metabolism | Antineoplastic Agents - chemistry | Mice, SCID | Ketoconazole - pharmacology | Antineoplastic Agents - metabolism | Animals | Drug Interactions | Fenretinide - chemistry | Mice, Nude | Fenretinide - pharmacokinetics | Mice, Inbred NOD | Antineoplastic Agents - pharmacokinetics | Mice | Molecular Structure | Enzymes | Bioavailability | Metabolites | Metabolism | Rodents | Research Papers
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text In vivo controlled release of fenretinide from long-acting release depots for chemoprevention of oral squamous cell carcinoma recurrence
by Nieto, Kari and Pei, Ping and Wang, Daren and Mallery, Susan R and Schwendeman, Steven P
International Journal of Pharmaceutics, ISSN 0378-5173, 03/2018, Volume 538, Issue 1-2, pp. 48 - 56
Local, long-acting release fenretinide (4HPR) millicylindrical implants were prepared and evaluated for their release kinetics and their ability to suppress... 
Local delivery | Fenretinide | PLGA | Oral cancer | In vivo release | Controlled release | HYDROPHOBIC FENRETINIDE | BILE-SALTS | MECHANISMS | IMPLANTS | SOLUBILITY | PLGA MICROSPHERES | PHARMACOLOGY & PHARMACY | DRUG-DELIVERY SYSTEMS | Polylactic Acid-Polyglycolic Acid Copolymer | Carcinoma, Squamous Cell - pathology | Humans | Drug Implants | Male | Drug Carriers - chemistry | Excipients - chemistry | Anticarcinogenic Agents - administration & dosage | Fenretinide - administration & dosage | Anticarcinogenic Agents - pharmacology | Mouth Neoplasms - prevention & control | Lactic Acid - chemistry | Neoplasm Recurrence, Local | Solubility | Fenretinide - pharmacology | Carcinoma, Squamous Cell - prevention & control | Rats, Sprague-Dawley | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Polyglycolic Acid - chemistry | Cell Line, Tumor | Drug Liberation | Mouth Neoplasms - pathology | Mice | Delayed-Action Preparations | Chemoprevention - methods | Prevention | Squamous cell carcinoma | Cancer | Biomedical engineering
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase I study of fenretinide delivered intravenously in patients with relapsed or refractory hematologic malignancies: A California cancer consortium trial
by Mohrbacher, Ann M and Yang, Allen S and Groshen, Susan and Kummar, Shivaani and Gutierrez, Martin E and Kang, Min H and Tsao-Wei, Denice and Reynolds, C. Patrick and Newman, Edward M and Maurer, Barry J
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 16, pp. 4550 - 4555
Purpose: A phase I study was conducted to determine the MTD, dose-limiting toxicities (DLT), and pharmacokinetics of fenretinide delivered as an intravenous... 
CARCINOMA-CELLS | APOPTOSIS | ONCOLOGY | LEUKEMIA | NEUROBLASTOMA-CELL-LINES | CERAMIDE | N-(4-HYDROXYPHENYL)RETINAMIDE | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Hematologic Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Fenretinide - administration & dosage | Adult | Female | Drug Administration Schedule | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Thrombocytopenia - chemically induced | California | Remission Induction | Fenretinide - therapeutic use | Fenretinide - pharmacokinetics | Hematologic Neoplasms - drug therapy | Aged | Infusions, Intravenous | Thrombocytopenia | Intravenous administration | Cell survival | Toxicity | Lymphocytes T | Pharmacology | Patients | Lymphoma | Anticancer properties | Consortia | Infusion | Lymphocytes B | Experimental design | Hypertriglyceridemia | Antitumor activity | Titration | Lymphomas | Plasma levels | Pharmacokinetics | Cancer | B-cell lymphoma | pharmacokinetics | phase I trial | fenretinide | intravenous | lymphoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Dynamics of ceramide generation and metabolism in response to fenretinide – Diversity within and among leukemia
by Morad, Samy A.F and Davis, Traci S and Kester, Mark and Loughran, Thomas P and Cabot, Myles C
Leukemia Research, ISSN 0145-2126, 2015, Volume 39, Issue 10, pp. 1071 - 1078
Highlights • Leukemias display diverse sensitivities to fenretinide. • Fenretinide enhances ceramide levels by de novo and sphingomyelinase pathways. •... 
Hematology, Oncology and Palliative Medicine | Ceramide metabolism | Acute myelogenous leukemia | Fenretinide/4-HPR | Sphingolipid metabolism | Leukemia | GLUCOSYLCERAMIDE SYNTHASE | DRUG-RESISTANCE | NEUROBLASTOMA-CELL-LINES | RESISTANT CANCER-CELLS | ORAL FENRETINIDE | ONCOLOGY | PHASE-I TRIAL | SERINE PALMITOYLTRANSFERASE | HEMATOLOGICAL MALIGNANCIES | MULTIDRUG-RESISTANCE | HEMATOLOGY | Antineoplastic Agents - metabolism | Cell Survival - drug effects | Reactive Oxygen Species - metabolism | Humans | Fenretinide - metabolism | Fenretinide - pharmacology | HL-60 Cells | Antineoplastic Agents - pharmacology | Leukemia - metabolism | Chromatography, Thin Layer | Ceramides - biosynthesis | Physiological aspects | Medical colleges | Index Medicus | acute myelogenous leukemia | leukemia | fenretinide | sphingolipid metabolism | 4-HPR | ceramide metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide
by Graves, Richard A and Ledet, Grace A and Glotser, Elena Y and Mitchner, Demaurian M and Bostanian, Levon A and Mandal, Tarun K
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 08/2015, Volume 76, pp. 1 - 9
Fenretinide is an anticancer drug with low water solubility and poor bioavailability. The goal of this study was to develop biodegradable polymeric... 
Nanoparticles | Fenretinide | Biodegradable | Formulation | PERMEABILITY | DRUG-DELIVERY | PHASE-II | TANDEM MASS-SPECTROMETRY | IN-VITRO MODELS | LOADED PLGA | BREAST-CANCER | TRANSPORT | PHARMACOLOGY & PHARMACY | PLGA NANOPARTICLES | CACO-2 CELLS | Intestinal Mucosa - metabolism | Humans | Polyethylene Glycols - chemistry | Antineoplastic Agents - administration & dosage | Chromatography, High Pressure Liquid | Intestinal Absorption | Drug Carriers | Antineoplastic Agents - metabolism | Fenretinide - chemistry | Esters - chemistry | Mass Spectrometry | Fenretinide - administration & dosage | Polyglactin 910 - chemistry | Caco-2 Cells | Microscopy, Electron, Scanning | Lactic Acid - chemistry | Administration, Oral | Solubility | Fenretinide - metabolism | Technology, Pharmaceutical - methods | Permeability | Antineoplastic Agents - chemistry | Spectrophotometry, Ultraviolet | Chemistry, Pharmaceutical | Particle Size | Polyglycolic Acid - chemistry | Calorimetry, Differential Scanning | Polymers - chemistry | Kinetics | formulation | biodegradable | fenretinide | nanoparticles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex
by Barry J. Maurer and Ondrej Kalous and David W. Yesair and Xiaqin Wu and Jitka Janeba and Vanessa Maldonado and Vazgen Khankaldyyan and Tomas Frgala and Bee-Chun Sun and R. Travis McKee and Stephen W. Burgess and Walter A. Shaw and C. Patrick Reynolds
Clinical Cancer Research, ISSN 1078-0432, 05/2007, Volume 13, Issue 10, pp. 3079 - 3086
Purpose: Fenretinide [ N -(4-hydroxyphenyl)retinamide (4-HPR)] is a cytotoxic retinoid that suffers from a wide interpatient variation in bioavailability when... 
LYM-X-SORB | neuroblastoma | fenretinide | 4-HPR | xenograft | BREAST-CANCER | GROWTH-INHIBITION | FENRETINIDE 4HPR | CARCINOMA CELLS | SOLID TUMORS | ONCOLOGY | PHASE-I TRIAL | INSULIN-RESISTANCE | LEUKEMIA-CELLS | TRANS-RETINOIC ACID | NEUROBLASTOMA-CELL-LINES | Powders | Fatty Acids - chemistry | Administration, Oral | Humans | Biological Availability | Peripheral Nervous System Neoplasms - drug therapy | Antineoplastic Agents - administration & dosage | Antineoplastic Agents - chemistry | Drug Delivery Systems | Tissue Distribution | Animals | Fenretinide - chemistry | Fenretinide - pharmacokinetics | Neuroblastoma - drug therapy | Cell Line, Tumor | Fenretinide - administration & dosage | Antineoplastic Agents - pharmacokinetics | Mice | Lysophosphatidylcholines - chemistry | Monoglycerides - chemistry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration
by Mata, Nathan L and Lichter, Jay B and Vogel, Roger and Han, Yun and Bui, Tam V and Singerman, Lawrence J
Retina, ISSN 0275-004X, 03/2013, Volume 33, Issue 3, pp. 498 - 507
Background: Excessive accumulation of retinol-based toxins has been implicated in the pathogenesis of geographic atrophy (GA). Fenretinide, an orally available... 
vitamin A | geographic atrophy | lipofuscin | fenretinide | retinol-binding protein | retinal pigment epithelium | age-related macular degeneration | N-retinylidene-N-retinylethanolamine | FUNDUS AUTOFLUORESCENCE PATTERNS | RETINOL-BINDING-PROTEIN | VITAMIN-A | JUNCTIONAL ZONE | BREAST-CANCER | A2E | VISUAL FUNCTION | PIGMENT EPITHELIUM | OPHTHALMOLOGY | DARK-ADAPTATION | Contrast Sensitivity - physiology | Double-Blind Method | Administration, Oral | Humans | Middle Aged | Geographic Atrophy - drug therapy | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Geographic Atrophy - blood | Retinol-Binding Proteins, Plasma - antagonists & inhibitors | Dose-Response Relationship, Drug | Fenretinide - therapeutic use | Geographic Atrophy - pathology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Surveys and Questionnaires | Aged | Visual Acuity - physiology | Vitamin A - blood | Fenretinide - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights